Skip to main content

Advertisement

SpringerLink
Log in

The dysregulation of plasma miR-497/FGF23 axis, and its association with clinical characteristics and major adverse cardiovascular event in female premature acute coronary syndrome patients

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Aim

MicroRNA-497 (miR-497) directly targets fibroblast growth factor 23 (FGF23) to participate in the pathology of acute coronary syndrome (ACS) by regulating atherosclerosis, inflammatory response, lipid metabolism, etc. This study intended to investigate the dysregulation of the miR-497/FGF23 axis, and its association with the major adverse cardiovascular event (MACE) in female premature ACS.

Methods

MiR-497 and FGF23 from plasma samples were detected by RT-qPCR and ELISA in 979 newly diagnosed female premature ACS patients and 100 healthy controls (HCs). MACE was recorded during follow-up (median: 27.0, range: 1.0–54.0 months) in female premature ACS patients.

Results

MiR-497/FGF23 axis was reduced in female premature ACS patients versus HCs [median (interquartile range): 0.7 (0.1–1.2) versus 1.9 (1.1–3.4)] (P < 0.001). Meanwhile, miR-497 negatively correlated with FGF23 in femal e premature ACS patients (P < 0.001), but not in HCs (P = 0.157). In female premature ACS patients, the miR-497/FGF23 axis was negatively associated with serum creatinine (P < 0.001), serum uric acid (P = 0.003), high-sensitivity C-reactive protein (P < 0.001), total cholesterol (P = 0.031), and low-density lipoprotein cholesterol (P = 0.003). The 1-year, 2-year, 3-year, and 4-year accumulating MACE rate was 2.9%, 8.6%, 16.7%, and 26.0%, respectively. Interestingly, a high level of miR-497/FGF23 axis predicted decreased accumulating MACE risk (P < 0.001). After adjustment by multivariate Cox’s regression analysis, the high miR-497/FGF23 axis (hazard ratio (HR) = 0.005, P = 0.001) independently correlated with reduced accumulating MACE risk.

Conclusion

The plasma miR-497/FGF23 axis represents favorable kidney function, decreased inflammation, and reduced lipid level; meanwhile, this axis possesses prognostic value in predicting decreased accumulating MACE risk in female premature ACS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Tsao CW, Aday AW, Almarzooq ZI et al (2022) Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145(8):e153–e639. https://doi.org/10.1161/CIR.0000000000001052

    Article  PubMed  Google Scholar 

  2. Bhatt DL, Lopes RD, Harrington RA (2022) Diagnosis and treatment of acute coronary syndromes: a review. JAMA 327(7):662–675. https://doi.org/10.1001/jama.2022.0358

    Article  PubMed  Google Scholar 

  3. Roux S, Bhatt DL (2020) Self-treatment for acute coronary syndrome: why not? Eur Heart J 41(23):2144–2145. https://doi.org/10.1093/eurheartj/ehaa302

    Article  CAS  PubMed  Google Scholar 

  4. Agewall S (2021) Antiplatelet treatment in coronary syndrome. Eur Heart J Cardiovasc Pharmacother 7(2):81–82. https://doi.org/10.1093/ehjcvp/pvab015

    Article  PubMed  Google Scholar 

  5. Jia S, Liu Y, Yuan J (2020) Evidence in guidelines for treatment of coronary artery disease. Adv Exp Med Biol 1177:37–73. https://doi.org/10.1007/978-981-15-2517-9_2

    Article  CAS  PubMed  Google Scholar 

  6. Mehilli J, Presbitero P (2020) Coronary artery disease and acute coronary syndrome in women. Heart 106(7):487–492. https://doi.org/10.1136/heartjnl-2019-315555

    Article  PubMed  Google Scholar 

  7. Hao Y, Liu J, Liu J et al (2019) Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation 139(15):1776–1785. https://doi.org/10.1161/CIRCULATIONAHA.118.037655

    Article  PubMed  Google Scholar 

  8. Jones DE, Braun M, Kassop D (2020) Acute coronary syndrome: common complications and conditions that mimic ACS. FP Essent 490:29–34

    PubMed  Google Scholar 

  9. Mohamed MO, Rashid M, Timmis A et al (2021) Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. Int J Cardiol 329:16–22. https://doi.org/10.1016/j.ijcard.2020.12.063

    Article  PubMed  Google Scholar 

  10. Haider A, Bengs S, Luu J et al (2020) Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J 41(13):1328–1336. https://doi.org/10.1093/eurheartj/ehz898

    Article  CAS  PubMed  Google Scholar 

  11. El-Menyar A, Ahmed E, Albinali H et al (2013) Mortality trends in women and men presenting with acute coronary syndrome: insights from a 20-year registry. PLoS ONE 8(7):e70066. https://doi.org/10.1371/journal.pone.0070066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ricci B, Cenko E, Vasiljevic Z et al (2017) Acute coronary syndrome: the risk to young women. J Am Heart Assoc 6 (12). https://doi.org/10.1161/JAHA.117.007519

  13. Kurpas A, Supel K, Idzikowska K, Zielinska M (2021) FGF23: a review of its role in mineral metabolism and renal and cardiovascular disease. Dis Markers 2021:8821292. https://doi.org/10.1155/2021/8821292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chung CP, Chang YC, Ding Y et al (2017) alpha-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cells. PLoS ONE 12(5):e0176817. https://doi.org/10.1371/journal.pone.0176817

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bockmann I, Lischka J, Richter B et al (2019) FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis. Int J Mol Sci 20(18). https://doi.org/10.3390/ijms20184634

  16. Yamada S, Giachelli CM (2017) Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho. Bone 100:87–93. https://doi.org/10.1016/j.bone.2016.11.012

    Article  CAS  PubMed  Google Scholar 

  17. Wang F, Ma R, Wang C (2022) Perioperative variation in serum FGF-23 level and its correlation with MACCE risk in unprotected left main coronary artery disease patients receiving coronary artery bypassing grafting. Front Surg 9:937342. https://doi.org/10.3389/fsurg.2022.937342

    Article  PubMed  PubMed Central  Google Scholar 

  18. Huang SS, Huang PH, Leu HB et al (2021) Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography. PLoS ONE 16(7):e0254835. https://doi.org/10.1371/journal.pone.0254835

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xu L, Hu X, Chen W (2019) Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis. J Nephrol 32(2):307–314. https://doi.org/10.1007/s40620-018-0557-4

    Article  CAS  PubMed  Google Scholar 

  20. Cui J, Ren Z, Zou W, Jiang Y (2017) miR-497 accelerates oxidized low-density lipoprotein-induced lipid accumulation in macrophages by repressing the expression of apelin. Cell Biol Int 41(9):1012–1019. https://doi.org/10.1002/cbin.10808

    Article  CAS  PubMed  Google Scholar 

  21. Zhang D, Chen X, Zheng D (2022) A novel MIR503HG/miR-497-5p/CCL19 axis regulates high glucose-induced cell apoptosis, inflammation, and fibrosis in human HK-2 cells. Appl Biochem Biotechnol 194(5):2061–2076. https://doi.org/10.1007/s12010-021-03776-6

    Article  CAS  PubMed  Google Scholar 

  22. Liu D, Zhou S, Mao H (2020) MicroRNA-497/fibroblast growth factor-23 axis, a predictive indictor for decreased major adverse cardiac and cerebral event risk in end-stage renal disease patients who underwent continuous ambulatory peritoneal dialysis. J Clin Lab Anal 34(6):e23220. https://doi.org/10.1002/jcla.23220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chinese Medical Association Emergency Physician Branch (2016) 2015 Guidelines for clinical practice of acute coronary syndrome in Chinese emergency department (Part II): diagnosis. Chin J Crit Care Med 36(1):9–11

    Google Scholar 

  24. Greenwood JP, Ripley DP, Berry C et al (2016) Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA 316(10):1051–1060. https://doi.org/10.1001/jama.2016.12680

    Article  PubMed  Google Scholar 

  25. Chen JM, Zhong YT, Tu C, Lan J (2020) Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis. World J Clin Cases 8 (16):3458–3464. https://doi.org/10.12998/wjcc.v8.i16.3458

  26. Akin F, Celik O, Ayca B et al (2015) Associations of fibroblast growth factor 23 and fetuin-A with coronary plaque burden and plaque composition in young adults. J Investig Med 63(4):613–619. https://doi.org/10.1097/JIM.0000000000000153

    Article  CAS  PubMed  Google Scholar 

  27. Xiao Y, Zhang X, Fan S et al (2016) MicroRNA-497 inhibits cardiac hypertrophy by targeting Sirt4. PLoS ONE 11(12):e0168078. https://doi.org/10.1371/journal.pone.0168078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chen T, Zhang X, Qian W et al (2022) Serum miR-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention. Bioengineered 13(4):8266–8276. https://doi.org/10.1080/21655979.2022.2051885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cao Z, Wang H, Zhu X (2021) The role of serum miR-497 on the predictive index of early diagnosis and poor prognosis of atherosclerosis cerebral infarction. Iran J Public Health 50 (5):927–937. https://doi.org/10.18502/ijph.v50i5.6110

  30. Scialla JJ, Wolf M (2014) Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10(5):268–278. https://doi.org/10.1038/nrneph.2014.49

    Article  CAS  PubMed  Google Scholar 

  31. Jafarzadeh M, Mohammad Soltani B, Ekhteraei Tousi S, Behmanesh M (2018) Hsa-miR-497 as a new regulator in TGFbeta signaling pathway and cardiac differentiation process. Gene 675:150–156. https://doi.org/10.1016/j.gene.2018.06.098

    Article  CAS  PubMed  Google Scholar 

  32. Zhang M, Yang D, Yu H, Li Q (2021) MicroRNA-497 inhibits inflammation in DSS-induced IBD model mice and lipopolysaccharide-induced RAW264.7 cells via Wnt/beta-catenin pathway. Int Immunopharmacol 101 (Pt B):108318. https://doi.org/10.1016/j.intimp.2021.108318

  33. Wu K, Tao G, Xu T et al (2021) Downregulation of miR-497-5p prevents liver ischemia-reperfusion injury in association with MED1/TIMP-2 axis and the NF-kappaB pathway. FASEB J 35(4):e21180. https://doi.org/10.1096/fj.202001029R

    Article  CAS  PubMed  Google Scholar 

  34. Wang J, Zhao SM (2021) LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497/thioredoxin-interacting protein axis in diabetic nephropathy. Life Sci 264:118728. https://doi.org/10.1016/j.lfs.2020.118728

    Article  CAS  PubMed  Google Scholar 

  35. Wu X, Weiszmann J, Ge H et al (2012) A unique FGF23 with the ability to activate FGFR signaling through both alphaKlotho and betaKlotho. J Mol Biol 418(1–2):82–89. https://doi.org/10.1016/j.jmb.2012.02.027

    Article  CAS  PubMed  Google Scholar 

  36. Takashi Y, Kawanami D (2022) The role of bone-derived hormones in glucose metabolism, diabetic kidney disease, and cardiovascular disorders. Int J Mol Sci 23(4). https://doi.org/10.3390/ijms23042376

  37. Rodriguez-Ortiz ME, Diaz-Tocados JM, Munoz-Castaneda JR et al (2020) Inflammation both increases and causes resistance to FGF23 in normal and uremic rats. Clin Sci (Lond) 134(1):15–32. https://doi.org/10.1042/CS20190779

    Article  CAS  PubMed  Google Scholar 

  38. Mace ML, Olgaard K, Lewin E (2020) New aspects of the kidney in the regulation of fibroblast growth factor 23 (FGF23) and mineral homeostasis. Int J Mol Sci 21(22). https://doi.org/10.3390/ijms21228810

  39. Degirolamo C, Sabba C, Moschetta A (2016) Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15(1):51–69. https://doi.org/10.1038/nrd.2015.9

    Article  CAS  PubMed  Google Scholar 

  40. Musgrove J, Wolf M (2020) Regulation and effects of FGF23 in chronic kidney disease. Annu Rev Physiol 82:365–390. https://doi.org/10.1146/annurev-physiol-021119-034650

    Article  CAS  PubMed  Google Scholar 

  41. Lang F, Leibrock C, Pandyra AA et al (2018) Phosphate homeostasis, inflammation and the regulation of FGF-23. Kidney Blood Press Res 43(6):1742–1748. https://doi.org/10.1159/000495393

    Article  CAS  PubMed  Google Scholar 

  42. Zhao Y, Zhang J (2021) Clinical implication of homocysteine in premature acute coronary syndrome female patients: its distribution and association with clinical characteristics and major adverse cardiovascular events risk. Medicine (Baltimore) 100(18):e25677. https://doi.org/10.1097/MD.0000000000025677

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China

    Yu Jiang, Wenyao Cai, Guorong Cai & Dingkun Wang

  2. Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang of Jiangxi, 330006, China

    Qinghua Wu

Authors
  1. Yu Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenyao Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guorong Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dingkun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qinghua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qinghua Wu.

Ethics declarations

Ethics approval

Approval from the Ethics Committee of our hospitals was gained.

Consent to participate

Written informed consent from all subjects was obtained.

Consent to publish

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 190 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Y., Cai, W., Cai, G. et al. The dysregulation of plasma miR-497/FGF23 axis, and its association with clinical characteristics and major adverse cardiovascular event in female premature acute coronary syndrome patients. Ir J Med Sci 192, 2105–2115 (2023). https://doi.org/10.1007/s11845-022-03256-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-022-03256-8

Keywords

Search

Navigation